{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T06:05:16Z","timestamp":1787983516804,"version":"build-2784847793"},"reference-count":34,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2017,3,28]],"date-time":"2017-03-28T00:00:00Z","timestamp":1490659200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA140217"],"award-info":[{"award-number":["R01CA140217"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R21CA195313-A1"],"award-info":[{"award-number":["R21CA195313-A1"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0174658","type":"journal-article","created":{"date-parts":[[2017,3,28]],"date-time":"2017-03-28T19:54:21Z","timestamp":1490730861000},"page":"e0174658","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":20,"title":["Multi-drug loaded micelles delivering chemotherapy and targeted therapies directed against HSP90 and the PI3K\/AKT\/mTOR pathway in prostate cancer"],"prefix":"10.1371","volume":"12","author":[{"given":"Bao","family":"Le","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ginny L.","family":"Powers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Tong","family":"Tam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Schumacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita L.","family":"Malinowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Steinke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glen","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul C.","family":"Marker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,3,28]]},"reference":[{"issue":"7","key":"ref1","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2165\/00003088-200342070-00005","article-title":"Pharmacological effects of formulation vehicles: implications for cancer chemotherapy","volume":"42","author":"AJ ten Tije","year":"2003","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"ref2","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/S0006-2952(03)00002-9","article-title":"Multidisciplinary utilization of dimethyl sulfoxide: pharmacological, cellular, and molecular aspects","volume":"65","author":"NC Santos","year":"2003","journal-title":"Biochem Pharmacol"},{"issue":"6","key":"ref3","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1158\/1078-0432.CCR-06-1863","article-title":"Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer","volume":"13","author":"DB Solit","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"9","key":"ref4","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1007\/s11095-008-9644-x","article-title":"Editorial for theme section on polymeric micelles for drug delivery","volume":"25","author":"GS Kwon","year":"2008","journal-title":"Pharm Res"},{"issue":"4","key":"ref5","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1021\/mp2000549","article-title":"A 3-in-1 polymeric micelle nanocontainer for poorly water-soluble drugs","volume":"8","author":"HC Shin","year":"2011","journal-title":"Mol Pharm"},{"issue":"10","key":"ref6","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1158\/1535-7163.MCT-11-0987","article-title":"Antitumor activity of Triolimus: a novel multidrug-loaded micelle containing Paclitaxel, Rapamycin, and 17-AAG","volume":"11","author":"JR Hasenstein","year":"2012","journal-title":"Mol Cancer Ther"},{"issue":"5s","key":"ref7","article-title":"Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial","volume":"32","author":"C. CY Sweeney","year":"2014","journal-title":"J Clin Oncol"},{"issue":"2","key":"ref8","doi-asserted-by":"crossref","first-page":"237","DOI":"10.2174\/156800909787580999","article-title":"Targeted therapy for advanced prostate cancer: inhibition of the PI3K\/Akt\/mTOR pathway","volume":"9","author":"TM Morgan","year":"2009","journal-title":"Curr Cancer Drug Targets"},{"issue":"49","key":"ref9","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1038\/onc.2013.206","article-title":"Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches","volume":"32","author":"T Karantanos","year":"2013","journal-title":"Oncogene"},{"issue":"18","key":"ref10","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1101\/gad.1965810","article-title":"Molecular genetics of prostate cancer: new prospects for old challenges","volume":"24","author":"MM Shen","year":"2010","journal-title":"Genes Dev"},{"issue":"3","key":"ref11","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S1535-6108(03)00215-0","article-title":"Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer","volume":"4","author":"S Wang","year":"2003","journal-title":"Cancer Cell"},{"issue":"13","key":"ref12","doi-asserted-by":"crossref","first-page":"6083","DOI":"10.1158\/0008-5472.CAN-06-4202","article-title":"Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development","volume":"67","author":"J Jiao","year":"2007","journal-title":"Cancer Res"},{"issue":"12","key":"ref13","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1002\/dvdy.23886","article-title":"Distinct expression patterns of Sulf1 and Hs6st1 spatially regulate heparan sulfate sulfation during prostate development","volume":"241","author":"RA Buresh-Stiemke","year":"2012","journal-title":"Dev Dyn"},{"issue":"1\u20132","key":"ref14","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0925-4773(00)00551-7","article-title":"Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation","volume":"101","author":"X Wu","year":"2001","journal-title":"Mech Dev"},{"issue":"11","key":"ref15","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"ES Antonarakis","year":"2014","journal-title":"N Engl J Med"},{"key":"ref16","unstructured":"Charles-River. Nu\/Nu Mouse Hematology <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.criver.com\/files\/pdfs\/rms\/nunu\/rm_rm_r_nunu_mouse_clinical_pathology_data.aspx2012\" xlink:type=\"simple\">http:\/\/www.criver.com\/files\/pdfs\/rms\/nunu\/rm_rm_r_nunu_mouse_clinical_pathology_data.aspx2012<\/ext-link>."},{"issue":"6","key":"ref17","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/mc.20628","article-title":"Rapamycin Regulates Akt and ERK Phosphorylation Through mTORC1 and mTORC2 Signaling Pathways","volume":"49","author":"XG Chen","year":"2010","journal-title":"Mol Carcinogen"},{"issue":"42","key":"ref18","doi-asserted-by":"crossref","first-page":"39858","DOI":"10.1074\/jbc.M206322200","article-title":"Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function","volume":"277","author":"AD Basso","year":"2002","journal-title":"J Biol Chem"},{"issue":"6","key":"ref19","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1016\/j.juro.2011.02.016","article-title":"Long-term androgen ablation and docetaxel up-regulate phosphorylated Akt in castration resistant prostate cancer","volume":"185","author":"T Kosaka","year":"2011","journal-title":"J Urol"},{"issue":"Pt 7","key":"ref20","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1242\/jcs.009530","article-title":"Akt-mediated phosphorylation of CDK2 regulates its dual role in cell cycle progression and apoptosis","volume":"121","author":"S Maddika","year":"2008","journal-title":"J Cell Sci"},{"issue":"2","key":"ref21","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ceb.2009.10.007","article-title":"mTOR and cancer: many loops in one pathway","volume":"22","author":"A Efeyan","year":"2010","journal-title":"Curr Opin Cell Biol"},{"issue":"3","key":"ref22","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","article-title":"mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt","volume":"66","author":"KE O'Reilly","year":"2006","journal-title":"Cancer Res"},{"issue":"12","key":"ref23","doi-asserted-by":"crossref","first-page":"8033","DOI":"10.1128\/MCB.19.12.8033","article-title":"Multiple components of the HSP90 chaperone complex function in regulation of heat shock factor 1 In vivo","volume":"19","author":"S Bharadwaj","year":"1999","journal-title":"Mol Cell Biol"},{"issue":"4","key":"ref24","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S0092-8674(00)81588-3","article-title":"Repression of heat shock transcription factor HSF1 activation by HSP90 (HSP90 complex) that forms a stress-sensitive complex with HSF1","volume":"94","author":"JY Zou","year":"1998","journal-title":"Cell"},{"issue":"6","key":"ref25","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1093\/carcin\/bgt111","article-title":"The HSP70 family and cancer","volume":"34","author":"ME Murphy","year":"2013","journal-title":"Carcinogenesis"},{"issue":"45","key":"ref26","doi-asserted-by":"crossref","first-page":"28697","DOI":"10.1074\/jbc.271.45.28697","article-title":"Hsp90 regulates androgen receptor hormone binding affinity in vivo","volume":"271","author":"Y Fang","year":"1996","journal-title":"J Biol Chem"},{"issue":"6","key":"ref27","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2174\/156800907781662248","article-title":"Cross-talk between the androgen receptor and the phosphatidylinositol 3-kinase\/akt pathway in prostate cancer","volume":"7","author":"Y Wang","year":"2007","journal-title":"Curr Cancer Drug Tar"},{"issue":"1","key":"ref28","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1530\/jrf.0.0470115","article-title":"Sensitivity of seminal vesicles to androgen stimulation during puberty in mice: effect of treatment duration","volume":"47","author":"TD McKinney","year":"1976","journal-title":"J Reprod Fertil"},{"issue":"9361","key":"ref29","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(03)12779-1","article-title":"Pathological and molecular aspects of prostate cancer","volume":"361","author":"AM DeMarzo","year":"2003","journal-title":"Lancet"},{"issue":"2","key":"ref30","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/BF01607049","article-title":"Keratin profiles in normal\/hyperplastic prostates and prostate carcinoma","volume":"421","author":"H Okada","year":"1992","journal-title":"Virchows Arch A Pathol Anat Histopathol"},{"issue":"5","key":"ref31","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.celrep.2014.08.002","article-title":"Luminal Cells Are Favored as the Cell of Origin for Prostate Cancer","volume":"8","author":"ZA Wang","year":"2014","journal-title":"Cell Rep"},{"issue":"3","key":"ref32","first-page":"311","article-title":"Targeted therapies: a new generation of cancer treatments","volume":"77","author":"DE Gerber","year":"2008","journal-title":"Am Fam Physician"},{"issue":"6","key":"ref33","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1007\/s00280-013-2163-4","article-title":"A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer","volume":"71","author":"R Amato","year":"2013","journal-title":"Cancer Chemoth Pharm"},{"key":"ref34","article-title":"Expert opinion on first-line therapy in the treatment of castration-resistant prostate cancer","author":"P Maroto","year":"2015","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0174658","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T09:09:20Z","timestamp":1719133760000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0174658"}},"subtitle":[],"editor":[{"given":"Chih-Pin","family":"Chuu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,3,28]]},"references-count":34,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2017,3,28]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0174658","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,28]]}}}